Ruth He, MD, PhD, discusses results from the CheckMate 9DW trial which evaluating nivolumab plus ipilimumab in the first-line setting for unresectable hepatocellular carcinoma.
Ruth He, MD, PhD, discusses results from the CheckMate 9DW trial which evaluating nivolumab plus ipilimumab in the first-line setting for unresectable hepatocellular carcinoma.
Given ongoing advancements in molecular residual disease (MRD) testing, should we rely on this modality to guide the diagnosis and treatment of colorectal cancer (CRC), or are we moving too fast into the unknown? Dr Janjigian provides an...
Given ongoing advancements in molecular residual disease (MRD) testing, should we rely on this modality to guide the diagnosis and treatment of colorectal cancer (CRC), or are we moving too fast into the unknown? Dr Janjigian provides an...
Alison Schram, MD, discusses the results from the eNRGy trial, evaluating the bispecific antibody against HER2 and HER3, zenocutuzumab for patients with NRG1 fusion-positive cancer.
Alison Schram, MD, discusses the results from the eNRGy trial, evaluating the bispecific antibody against HER2 and HER3, zenocutuzumab for patients with NRG1 fusion-positive cancer.
Nilanjan Ghosh, MD, PhD, FACP discusses new updates in treatment strategies for patients with relapsed/refractory diffuse large B-cell lymphoma including bispecific antibodies and CAR T-cell therapy.
Nilanjan Ghosh, MD, PhD, FACP discusses new updates in treatment strategies for patients with relapsed/refractory diffuse large B-cell lymphoma including bispecific antibodies and CAR T-cell therapy.
